Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice. (PubMed, Life Sci) - Sep 30, 2026 - "This effect entails comprehensive improvement of metabolic homeostasis, reduced hepatic steatosis, and increased systemic energy expenditure. Formal combination interaction analysis indicated synergistic effects across key metabolic endpoints."
Journal • Preclinical • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • CPT1A
|
|
Ali Akbar Soleimani; Gholamreza Taheripak; Masoume Aliabadi; Mitra Nourbakhsh; Reza Meshkani
|